Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal

Haloperidol and reduced haloperidol plasma concentrations were measured in twelve schizophrenic patients upon cessation of haloperidol decanoate (HLD) treatment. Each patient received HLD 100 mg every 4 weeks for five injections. After the fifth injection, HLD was discontinued.Haloperidol and reduce...

Full description

Saved in:
Bibliographic Details
Published in:Schizophrenia research 1993-03, Vol.9 (1), p.35-40
Main Authors: Chang, Wen-Ho, Lin, Shih-Ku, Juang, Dong-Juiing, Chen, Li-Chin, Yang, Chih-Hsien, Hu, Wei-Herng, Chien, Ching-Paio, Lam, Y.W.Franics, Jann, Michael W.
Format: Article
Language:English
Subjects:
Adult
Biological and medical sciences
Female
Half-Life
Haloperidol
Haloperidol - adverse effects
Haloperidol - analogs & derivatives
Haloperidol - pharmacokinetics
Haloperidol - therapeutic use
Haloperidol decanoate
Humans
Injections, Intramuscular
Male
Medical sciences
Metabolic Clearance Rate - physiology
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Reduced haloperidol
Schizophrenia - drug therapy
Schizophrenic Psychology
Substance Withdrawal Syndrome - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Haloperidol and reduced haloperidol plasma concentrations were measured in twelve schizophrenic patients upon cessation of haloperidol decanoate (HLD) treatment. Each patient received HLD 100 mg every 4 weeks for five injections. After the fifth injection, HLD was discontinued.Haloperidol and reduced haloperidol plasma concentrations were obtained prior to cessation and at weeks 1, 3, 4, 5, 7, 9, 11, and 13 post-injection. Haloperidol and reduced haloperidol plasma concentrations were assayed by HPLC. Both haloperidol and reduced haloperidol plasma concentrations were detectable 13 weeks post HLD discontinuation. Maximal haloperidol plasma concentrations were observed at one week post cessation and gradually declined. The mean elimination half-life for haloperidol was 27.4 ± 8.6 days (range 19.0– 47.0 days). Reduced haloperidol plasma concentrations declined very slowly. Our results show that both haloperidol and reduced haloperidol plasma concentrations can remain for extended time periods after HLD is discontinued.
ISSN:0920-9964
1573-2509
DOI:10.1016/0920-9964(93)90007-6